A significant volume of new M&A deals during 2021 are expected to involve cell and gene therapy developers as in recent years—but with an emerging twist resulting from some recent clinical disappointments for autologous treatments . . .
{iframe}https://www.genengnews.com/gen-edge/ey-firepower-report-biopharma-ma-poised-to-rebound-in-2021/amp/{/iframe}